一分钟看懂
这是一项关于前列腺癌的I 期研究，登记的药物或干预包括JUR-003，当前状态为招募中。登记地点显示中国Grand Rapids、Lake Success、Nashville有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
JUR-003 · I 期
登记条件中文摘要
登记的基本范围为男性，年龄18 岁；另列出6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- START Midwest · Grand Rapids
- START New York · Lake Success
- SCRI Oncology Partners · Nashville
公开的入选条件
- * Must be ≥18 years of age at the time the informed consent form (ICF) is signed.
- * Has a histologically or cytologically confirmed adenocarcinoma of the prostate.
- * Has either of the following:
- 1. Measurable disease per RECIST v1.1 (with PCWG3 modifications)
- 2. Evaluable disease per PCWG4, as assessed by the local site Investigator/radiology
- 3. For Part 2.1B (omPC expansion) only: PSMA-avid disease on PSMA-PET, defined as lesion(s) demonstrating uptake above blood pool (PSMA score ≥1) and assessed by the Investigator as consistent with metastatic prostate cancer, in the setting of biochemical recu
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07824349；登记信息更新于 2026-10-02。